Cargando…
TTR: Time in Therapeutic Range or “The Troublesome Report”?
Autor principal: | Reiffel, James A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MediaSphere Medical
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252706/ https://www.ncbi.nlm.nih.gov/pubmed/32477700 http://dx.doi.org/10.19102/icrm.2019.100103 |
Ejemplares similares
-
Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum
por: Reiffel, James A.
Publicado: (2017) -
Which is more troublesome, insulin or needle?
por: Menaka, R., et al.
Publicado: (2008) -
Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy “in disguise”
por: Grandis, Marina, et al.
Publicado: (2018) -
Therapeutic education programme in TTR-FAP
por: Théaudin, Marie, et al.
Publicado: (2015) -
Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation
por: Bulinski, Catherine, et al.
Publicado: (2022)